Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Study in Patients With Solid Tumours

NCT00496028

Neoplasms

COMPLETED PHASE1

AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

NCT00704366

Solid Tumor

COMPLETED PHASE1

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316

Advanced Solid Malignancy Safety and Tolerability Pharmacokinetics +11 more

COMPLETED PHASE1

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

NCT01112397

Solid Malignancies

TERMINATED PHASE1

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

NCT00613652

Cancer Tumors Carcinoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Non Small Cell Lung Cancer Epithelial Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AZD0530 + carboplatin and paclitaxel

AZD0530 in combination with carboplatin and paclitaxel

Group Type EXPERIMENTAL

AZD0530

Intervention Type DRUG

film coated tablet, PO, daily

Carboplatin

Intervention Type DRUG

intravenous, 3 weeks

paclitaxel

Intervention Type DRUG

intravenous, 3 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD0530

film coated tablet, PO, daily

Intervention Type DRUG

Carboplatin

intravenous, 3 weeks

Intervention Type DRUG

paclitaxel

intravenous, 3 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paraplatin Taxol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Japanese patients with non small cell lung cancer or epithelial ovarian cancer
* Must be suitable for treatment with carboplatin and paclitaxel
* Relatively good overall health other than cancer

Exclusion Criteria

* Poor bone marrow function (not producing enough blood cells).
* Poor liver or kidney function.
* Patients unable to discontinue drugs known to be potent inhibitors or inducers of CYP3A4 within 2 weeks prior to registration

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No